New drug ABBV-722 tested in humans for first time
NCT ID NCT06673238
First seen Jun 25, 2026 · Last updated Jul 28, 2026 · Updated 3 times
Summary
This is a first-in-human study to see if ABBV-722 is safe and how the body handles it. About 95 healthy adults will receive either the drug or a placebo. The goal is to check for side effects and measure drug levels in the blood, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ABBV-722
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Acpru /Id# 270279
Grayslake, Illinois, 60030, United States
-
Altasciences Clinical Los Angeles /ID# 280183
Cypress, California, 90630, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?